T56-LIMKi inhibited their tumor formation in vivo in a dose-dependent manner and reduced p-cofilin levels of the tumor cells with no sign of attendant toxicity (Fig. 6 and Fig. 7). The gene discussed is CFL1; the disease is neoplasm.